Nervoid
Nervoid Inc., founded in 2025 and headquartered in Cambridge, Massachusetts (750 Main Street), is a computer-vision/AI startup that converts standard microscopy images of cells into gene-expression and signaling-pathway readouts — inferring a cell's molecular state without sequencing or destructive assays.
Position in SVTR
Snapshot 2026-10-28- Startup SignalsRankedof 2,177new
- Life SciencesRankedof 231
- AutomationRankedof 199
- AI for ScienceRankedof 107
About
Nervoid Inc., founded in 2025 and headquartered in Cambridge, Massachusetts (750 Main Street), is a computer-vision/AI startup that converts standard microscopy images of cells into gene-expression and signaling-pathway readouts — inferring a cell's molecular state without sequencing or destructive assays. It targets drug discovery and precision medicine, delivered as a SaaS product integrated with existing screening hardware. The company is a Resident Company of The Engine (an MIT-affiliated deep-tech incubator) and is backed by AI BioHub; it is currently at the incubator/accelerator stage.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Nervoid
Nervoid Inc., founded in 2025 and headquartered in Cambridge, Massachusetts (750 Main Street), is a computer-vision/AI startup that converts standard microscopy images of cells into gene-expression and signaling-pathway readouts — inferring a cell's molecular state without sequencing or destructive assays. It targets drug discovery and precision medicine, delivered as a SaaS product integrated with existing screening hardware. The company is a Resident Company of The Engine (an MIT-affiliated deep-tech incubator) and is backed by AI BioHub; it is currently at the incubator/accelerator stage.
—
United States
BusinessLatest roundTotal raisedDate- Portal Biotechnologies
Silicon micropore mechanical-poration intracellular delivery hardware (Gateway, Millibooster, Galaxy-i, etc.) and consumables for pharma companies, academic hospitals and biotech labs, with a DARPA contract, replacing viral vectors and lipid nanoparticles for cell engineering, gene editing, RNA therapy and AI drug discovery research
$5M
$5M - insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Warp Sciences
AI and robotic automated labs for synthesizing and testing drug molecule variants
$215M · 2026-10 · Valuation $865M
$215MValuation $865M
China
BusinessLatest roundTotal raisedDate- Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - BioGeometry
BioGeometry is an AI-native biopharma company using geometric deep learning and generative AI to design proteins and antibodies; its GeoFlow generative biomolecule model and GeoBiologics platform are coupled with high-throughput wet-lab validation, with 20+ BD partnerships with pharma companies.
Series A · $100M · 2026-10
$100M - TandemAI
Drug molecule discovery platform rebuilt around "AI + physics-based modeling + wet lab"
Series A · $80M · 2025-11
$80M
Europe
BusinessLatest roundTotal raisedDate- Vitrue Health
Prevents and manages employee neck and back pain at work by analyzing movement and posture with computer vision and AI
Undisclosed · $4M · 2024-03
$4M - bit.bio
Human cell programming technology for drug discovery and toxicology
Series C · $72M · 2026-01
$72M - Teton.ai
AI and computer vision for predictive care in senior care facilities and hospitals
Series A · $20M · 2025-09
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- Intrepid Labs
Autonomous labs combining AI, robotics and chemistry to accelerate drug compound formulation
Seed · $11M · 2025-05
$11M - Cloudphysician
RADAR tele-ICU platform and AI tools (NETRA, AIRA, HERA, SWARA) for remote critical care at private and public hospitals in India
$4M
$4M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in US East Coast
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.